Publication/Presentation Date
6-30-2020
Abstract
The treatment of metastatic breast cancer has undergone significant changes in recent years. New classes of medications have been approved by the Food and Drug Administration (FDA) for use in clinical practice to extend progression-free survival and overall survival along with increasing response rate. Here, we present a case report of pneumonitis as a rare side effect of palbociclib in the treatment of metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (ERBB2-) breast cancer in addition to endocrine therapy. We also review the literature for other reports of pneumonitis during treatment with palbociclib. Through this case report and review of the literature, we aim to shed light on this rare side effect of palbociclib along with its successful management.
Volume
12
Issue
6
First Page
8929
Last Page
8929
ISSN
2168-8184
Published In/Presented At
Sarkisian, S., Markosian, C., Ali, Z., & Rizvi, M. (2020). Palbociclib-Induced Pneumonitis: A Case Report and Review of the Literature. Cureus, 12(6), e8929. https://doi.org/10.7759/cureus.8929
Disciplines
Medicine and Health Sciences
PubMedID
32760629
Department(s)
Department of Medicine, Hematology-Medical Oncology Division, Hematology-Medical Oncology Division Fellows and Residents, Department of Medicine Faculty, Department of Medicine Fellows and Residents, Fellows and Residents
Document Type
Article